#JPM23: Is 2023 go­ing to be a bet­ter year for biotech deal­mak­ing?

Last year of­fered a dis­ap­point­ing stretch for biotech, with few­er deals than ex­pect­ed and lots more head­winds. End­points News Ed­i­tor-in-Chief John Car­roll sat down with some of the in­dus­try’s top deal­mak­ers to ex­plore what hap­pened, and what’s ahead in 2023. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

John Car­roll:

I’d say this is one of the most im­por­tant con­ver­sa­tions that’s go­ing on right now. Par­tic­u­lar­ly, of course, at JP Mor­gan, be­cause so many peo­ple have come here, specif­i­cal­ly to get in­volved in a deal, to see what they can do about a deal, to see what the deal po­ten­tial is, where things are head­ed, what the trends are. Every­thing that we’re go­ing to be cov­er­ing here in the next hour.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.